Cellectis S.A. Business Summary

Cellectis S.A. is a clinical-stage biotechnology company that generates revenue primarily through high-value strategic partnerships, licensing agreements, and milestone-based R&D collaborations, most notably its 2023-initiated Joint Research Collaboration Agreement with AstraZeneca, which currently accounts for over 98% of its top-line growth. The company operates through two primary business segments: its allogeneic Chimeric Antigen Receptor T-cell (UCART) pipeline targeting hematological malignancies and solid tumors, and its gene-edited hematopoietic stem and progenitor cell (HSPC) platform for genetic disorders. As of March 2026, Cellectis has transitioned into a late-stage development entity, centered on the pivotal Phase 2 BALLI-01 trial for its lead candidate, lasme-cel (UCART22). In a competitive landscape dominated by Kite Pharma (Gilead), CRISPR Therapeutics, and Fate Therapeutics, Cellectis distinguishes itself as a pioneer in TALEN-based genome editing, maintaining a unique market position by controlling the end-to-end value chain through in-house GMP manufacturing facilities in Paris and Raleigh. The company was co-founded in 1999 by Dr. André Choulika and Dr. David Sourdive, both of whom remain central to the leadership team; Choulika serves as Chief Executive Officer and is a recognized pioneer in nuclease-based genome editing from his tenure at Boston Children’s Hospital, while Sourdive serves as Executive Vice President of CMC & Manufacturing. The executive suite is further bolstered by Chief Financial and Business Officer Arthur Stril, Chief Scientific Officer Philippe Duchateau—a gene-editing veteran since 2001—and Chief Medical Officer Adrian Kilcoyne. The board is chaired by Dr. Jean-Pierre Garnier, the former CEO of GlaxoSmithKline, and includes notable representation from lead investor AstraZeneca via Dr. Tyrell J. Rivers. This leadership pedigree, combined with a cash runway extending into late 2027, positions the firm to leverage its proprietary TALEN technology against the broader industry shift toward scalable, off-the-shelf cellular immunotherapies.